Company: PTPI
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001104659-25-025104
Chunk: 35

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 35
---
 minimum per share bid price requirements for continued listing on The Nasdaq
Capital Market. We believe that a range of Reverse Stock Split ratios provides us with the most flexibility to achieve the desired results
of the Reverse Stock Split. The Reverse Stock Split is not intended as, and will not have the effect of, a “going private transaction”
covered by Rule 13e-3 promulgated under the Exchange Act. The Reverse Stock Split is not intended to modify the rights of existing
stockholders in any material respect.

If the Reverse Stock Split
Proposal is approved by our stockholders and the Reverse Stock Split is effected, up to every 500 shares of our outstanding Common Stock
would be combined and reclassified into one share of Common Stock. Notwithstanding approval of the Reverse Stock Split Proposal by our
stockholders, the Board will have the sole authority to elect whether or not and when to amend our Charter to effect the Reverse Stock
Split. If the Reverse Stock Split Proposal is approved by our stockholders, the Board will make a determination as to whether effecting
the Reverse Stock Split is in the best interests of the Company and our stockholders in light of, among other things, the Company’s
ability to increase the trading price of our Common Stock to meet the minimum stock price standards of the Nasdaq Capital Market without
effecting the Reverse Stock Split, the per share price of the Common Stock immediately prior to the Reverse Stock Split and the expected
stability of the per share price of the Common Stock following the Reverse Stock Split. If the Board determines that it is in the best
interests of the Company and its stockholders to effect the Reverse Stock Split, it will hold a Board meeting to determine the ratio of
the Reverse Stock Split. For additional information concerning the factors the Board will consider in deciding whether to effect the Reverse
Stock Split, see “- Determination of the Reverse Stock Split Ratio” and “- Board Discretion to Effect the Reverse Stock Split.”

At the Company’s 2024
Annual Meeting of Stockholders held on November 20, 2024, the stockholders of the Company approved a proposal to authorize the Board to
amend the Company’s Charter to effect a reverse stock split of the Company’s Common Stock at a ratio between 1-for-2 and 1-for-25
with the ultimate ratio to be determined by the Board in its sole discretion (the “Authorized Reverse Stock Split”). The Reverse
Stock Split Proposal to be approved at this Special Meeting seeks stock